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ing of perspectives and rationales for decisions. Intended to measure value in its 
broad sense, the framework supports sustained application of MCDA in health care 
decisionmaking.
HT3
IdenTIfyIng RecenT TRends In HealTH TecHnology assessmenTs foR 
cRoHn’s dIsease
Mahendraratnam N., Inocencio TJ., Gaffney J, Agatep BC., Hughes KE.
Avalere Health LLC, Washington, DC, USA
Objectives: To identify the types of coverage recommendations made by key 
ex-US health technology assessment (HTA) organizations for biologic treatments 
in Crohn’s disease (CD) and to understand how these organizations interpret evi-
dence to support these recommendations. MethOds: Publicly available HTAs on 
CD from January 2009 to June 2013 for the following organizations were reviewed: 
CADTH (Canada), CONITEC (Brazil), HAS (France), IQWiG (Germany), NICE (UK), PBAC 
(Australia), and ISCIII (Spain). HTAs were identified using an HTA search engine 
and were supplemented with separate manual searches for CD-related reports on 
each HTA organization’s website. When additional context was needed to evaluate 
the HTA with the most recent recommendations, older HTAs were identified and 
reviewed. For each organization, the recommendation and corresponding clinical 
and economic rationales were reviewed and extracted. Results: In total, nine HTAs 
were reviewed across five organizations; no HTAs on CD from IQWiG or ISCIII were 
identified. All HTAs endorsed the use of infliximab and adalimumab for CD from a 
clinical perspective. Recommendations for subpopulations including fistulizing dis-
ease, pediatrics, and prior/concurrent corticosteroid use varied. Recommendations 
were consistent with the host country’s approved labeled indications when appro-
priate cost thresholds were met, with the exception of PBAC, where adalimumab was 
additionally deemed appropriate for fistulizing disease, and CONITEC, where certoli-
zumab was not endorsed due to safety concerns. Research gaps identified include 
the lack of head-to-head trials for adalimumab vs. infliximab and the paucity of 
long-term clinical and economic evidence. cOnclusiOns: Infliximab and adali-
mumab generally received positive endorsements in CD, despite being frequently 
scrutinized by HTA organizations for their high costs. The expiration of patents and 
the introduction of biosimilars will likely shift how HTA entities evaluate clinical, 
economic, and humanistic evidence for biologic treatments for CD in the future.
HT4
cosT-effecTIveness RevIews By HTa agencIes: a compaRIson of 
facToRs leadIng To UnfavoURaBle RevIews foR oncology agenTs
Smith N., Beckerman R.
CBPartners, New York, NY, USA
Objectives: The purpose of this study was to identify factors leading to unfa-
vourable reviews of cost-effectiveness analyses (CEAs) for oncology products by 
comparing recent summary reports from multiple HTA agencies. MethOds: We 
utilised reports issued by HTA agencies of the UK (NICE), Scotland (SMC), Canada 
(pCODR), and Australia (PBAC) for this study due to their detailed and publicly avail-
able evaluations of CEA submissions. We examined the factors driving unfavourable 
appraisals by comparing recent reports of 13 selected oncology drugs launched 
between January 2012 and December 2013. The following factors were examined and 
compared as predictors for negative decisions: (1) nature of the modelled patient 
population, (2) comparator selection, (3) survival analysis approach, and (4) sensi-
tivity analyses performed. Results: Issues related to one or more of these factors 
were often cited as leading to higher and more uncertain ICER values that HTA 
bodies viewed unfavourably. The SMC and NICE frequently took issue whether the 
patient populations sourced as inputs into the CEAs were representative of the 
intended indication in each respective country. All HTA agencies took issue with 
survival analysis methods that assumed a carry-over of benefit into post-treatment 
states. Similarly, HTA bodies typically critically examined the extrapolation meth-
odology of studies with immature survival data. Although various combinations 
of these identified factors were likely to lead to negative HTA decisions, robust 
sensitivity analyses (especially regarding extrapolation methods and input sources) 
that clearly identified the factors driving ICER values were cited favourably by HTA 
agencies. cOnclusiOns: Manufacturers must carefully select the survival analy-
sis approach that is suitable for their asset given the clinical data available, such 
that the benefit of their product is not overstated; performing robust sensitivity 
analyses to account for uncertainty may help to maximise favourable HTA appraisal 
outcomes in CEA markets.
medIcaTIon adHeRence sTUdIes
ma1
non-adHeRence Is assocIaTed wITH pooReR HealTH oUTcomes among 
women cURRenTly TReaTed foR BReasT canceR wITH oRal endocRIne 
THeRapy
Goren A1, Geynisman DM2
1Kantar Health, New York, NY, USA, 2Fox Chase Cancer Center Temple Health, Philadelphia, PA, 
USA
Objectives: Non-adherence rates with oral endocrine therapy (ET) in women 
with breast cancer (BC) are 25%-50% and lead to inferior survival. Understanding 
the effect of non-adherence on health outcomes is necessary to develop effec-
tive interventions. This study examined real-world non-adherence and health 
outcomes among women using ET. MethOds: Female respondents from the 
2010-2012 U.S. National Health and Wellness Survey were included if reporting a 
diagnosis of BC and treatment with aromatase inhibitors (n= 261), selective estrogen 
receptor modulators (n= 113), or their combination (n= 7). The Morisky Medication 
Adherence Scale (MMAS-4 or MMAS-8, modified for use in oncology) was used to 
assess adherence, standardized using z-scores. Descriptive analyses examined 
adherence, sociodemographics, and health behaviors. Bivariate analyses com-
formulary listing recommendations to publicly funded drug plans. This study aims 
to determine the implications of implementing CDR recommendations. MethOds: 
CDR reviews from December 2010 to December 2012, for which an economic evalu-
ation was submitted by the manufacturer, were assessed. A framework was devel-
oped where templates were created in Microsoft Excel for each drug submission to 
consider two scenarios: an uptake scenario (CDR recommendation implemented), 
and a counterfactual scenario (CDR recommendation not implemented). Drug costs 
and quality adjusted life years (if applicable) for both scenarios were determined at 
the population level using patient numbers reported in the manufacturer’s budget 
impact analyses. The incremental net benefit was calculated, based on a willing-
ness-to-pay of $50,000. In addition, sensitivity analyses were conducted to consider 
variation around the counterfactual scenario. Results: Based on the results for the 
55 drugs for which cost-utility or a cost-minimization analysis was submitted, the 
total incremental net benefit of implementing a CDR recommendation was calcu-
lated to be over 1 billion dollars over a 1-year time frame for participating provincial 
drug plans. Detailed sensitivity analysis explored the uncertainty around these 
estimates. cOnclusiOns: Overall, the 10 drug plans included for this analysis 
would realize significant benefit by implementing CDR recommendations. Based 
on this research, a framework to assess the impact of CDR recommendations is 
being developed. Next steps include, consideration of disease specific estimates 
of net benefit and the inclusion of all participating drug plans to provide broader 
implications of overall CDR impact in Canada.
HealTH TecHnology assessmenT sTUdIes
HT1
RecenT HealTH TecHnology assessmenT decIsIons acRoss THe gloBe: 
a focUs on oncology
Clark RS., Zagadailov E., Bramley T.
Xcenda, Palm Harbor, FL, USA
Objectives: Due to a substantial oncology burden across the globe, there is an 
increasing need for innovative, more effective oncology treatments. Although the 
decision-making process differs among nations, health technology assessments 
(HTAs) aim to produce policies that achieve optimal value while improving patient 
care and health outcomes. The objective of this analysis was to evaluate recent 
patterns in oncology-based HTA decisions in selected countries. MethOds: HTA 
surveillance was conducted for Australia, Canada, France, Germany, and the United 
Kingdom (UK) from January 1, 2012 to August 31, 2013 (19 months). Oncology-based 
HTAs were evaluated by therapeutic area, decision, and rationale for the decision. 
Decisions were categorized as favorable, unfavorable, mixed (ie, both favorable 
and unfavorable), and neutral (ie, deferral). Results: 67 oncology-related HTAs 
were published in the study timeframe. Across studied nations, 38 (57%) decisions 
were favorable, 25 (37%) unfavorable, 1 (1%) mixed, and 3 (4%) neutral. Of those 
unfavorable decisions, 13 were rejected for insufficient benefit to justify the high 
cost (ie, improperly high incremental cost-effectiveness ratio [ICER]), 9 for insuf-
ficient or unproven clinical benefit vs the most appropriate comparator, and 3 for 
incomplete or improper submission. Excluding mixed and neutral decisions, France 
was associated with the highest percentage of favorable decisions (14 of 15; 93%), 
followed by Germany (9 of 14; 64%), Australia (11 of 20; 55%), and the UK (4 of 14; 
29%). cOnclusiOns: Based on the last 19 months of oncology-based HTAs, over 
50% of decisions were favorable. The most significant factor leading to rejection for 
oncology products is the inability to prove cost-effectiveness vs the most appropri-
ate comparator, followed by unproven clinical benefit. This analysis suggests that 
manufacturers would have more success with HTA decisions, particularly in the UK, 
if more robust health economic and clinical data are generated.
HT2
assessIng THe valUe of TReaTmenTs foR RaRe dIseases UsIng an 
mcda-Based appRoacH: meTHodologIcal and eTHIcal foUndaTIons of 
cRITeRIa selecTIon and fRamewoRk developmenT
Wagner M1, Khoury H1, Willet J2, Rindress D1, Goetghebeur M1
1LASER Analytica, Montreal, QC, Canada, 2LASER Analytica, New York, NY, USA
bAckgROund: Appraising rare disease treatments involves multiple issues and 
represents a significant challenge for HTA agencies. Multicriteria-approaches are 
uniquely suited to assess their real life value. Objectives: were to develop a frame-
work adapted to rare diseases while remaining compatible with other therapeutic 
areas for broad application. MethOds: Adaptation of the framework to rare dis-
eases was based on methodological and ethical principles underlying the EVIDEM 
framework, informed by issues and policies specific to rare diseases, which were 
identified through literature review and survey, and guided by pragmatic considera-
tions of real life application in participatory processesCriteria selection followed 
MCDA principles: completeness; non-redundancy; operationalizability; and inde-
pendence. MCDA model mechanics and sensitivity analyses were designed based 
on a review of MCDA modeling. Results: Quantitative criteria of the framework are 
organized into a hierarchical MCDA model consisting of six domains of value (top-
level criteria): Need, Type of benefit, Outcomes, Economic consequences, Knowledge, and 
Established priorities. Each domain includes criteria and subcriteria, each contributing 
to the final output of the model, i.e., the Value Estimate. The model explicitly takes 
into account aspects of rare diseases, including: disease complexity; treatment 
outcomes complexity; multiple economic and social consequences; data limita-
tions and innovative approaches to tackle these; and health care system priorities. 
Weighting and scoring methodologies capture individual perspectives and judg-
ments on the meaning of data while allowing for full exploration of uncertainty 
through six types of sensitivity analyses. Qualitative criteria support consideration 
of the impact of contextual issues. cOnclusiOns: This framework promotes a 
comprehensive, transparent and systematic appraisal of rare disease treatments 
while remaining applicable to any therapy. Although numerical outputs are pro-
duced, the framework is intended to support deliberative processes that allow shar-
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tematic literature review was conducted to identify articles published in English 
language journals that evaluated the rate of adherence to medications in patients 
with chronic disease. Relevant studies were identified using PubMed, EMBASE, and 
the Cochrane Library databases with a search window from January 2002 through 
August 2013. Twenty-two observational studies reporting adherence were identified 
by two independent reviewers. Of these publications, 7 reported complete informa-
tion on relevant endpoints of studies in patients with osteoporosis. Meta-analyses 
examined 1) mean difference (MD) in adherence (defined using average medica-
tion possession ratio [MPR]) between QW and QD dosing groups and 2) odds ratio 
for adherence (defined using a cut-off of MPR ≥ 80%) for QW versus QD dosing. 
Heterogeneity was assessed using I42 values and meta-analyses utilized both fixed 
and random effects models. Results: The random effects meta-analysis revealed a 
significantly greater MPR with QW compared to QD dosing (pooled MD= 12.29% [95% 
confidence interval (CI) 10.76%-13.82%]; n= 9 [data reported in 7 publications]). Due 
to the high level of heterogeneity (I2= 83.4%), the fixed effects model results are not 
appropriate to report for the pooled MD. When examining the odds ratio for adher-
ence, both fixed and random effects models provided similar results due to the low 
level of heterogeneity (I2= 7.9%; n= 5 [data reported in 3 publications]). Using either 
model, the pooled odds of being adherent (MPR ≥ 80%) in the QW dosing group was 
approximately 1.9 times the odds in the QD dosing group (random effects OR= 1.90 
[95% CI 1.81-2.00]; fixed effects OR= 1.92 [95% CI 1.84-1.99]). cOnclusiOns: In our 
meta-analysis, QW dosing was associated with higher MPR values and greater odds 
of adherence compared to QD dosing in patients with osteoporosis.
RIsk managemenT sTUdIes
RI1
pRedIcTIng THe RIsk of closTRIdIUm dIffIcIle InfecTIon Upon 
admIssIon: a RIsk scoRe To IdenTIfy paTIenTs foR pHaRmacIsT 
anTIBIoTIc RevIew and edUcaTIon
Smith DH, Kuntz JL, Petrik AF, Yang X, Thorp ML, Spindel SJ, Barton T, Barton K,  
Labreche M, Johnson ES
Kaiser Permanente Northwest, Portland, OR, USA
Objectives: Increasing morbidity related to Clostridium difficile infection (CDI) moti-
vates methods to identify patients for preventive measures. We developed a risk 
score that can be calculated automatically upon hospital admission based on an 
electronic health record and used by inpatient pharmacists to identify patients who 
would benefit from antibiotic review and patient education. MethOds: We assem-
bled a cohort of Kaiser Permanente Northwest patients with a hospital admission 
between 2005 and 2012 and identified CDIs in the six months following admission, 
inclusive of the initial hospitalization. Using Cox regression, we synthesized a priori 
predictors into a risk score, in which a higher number of points indicated higher risk 
for CDIs. We plotted the observed six-month CDI risk for each decile of predicted 
risk. Results: We identified 721 CDIs in the six months following 54,186 hospital 
admissions, an incidence of 13.8 CDIs per 1000 patients. Patients with the highest 
predicted CDI risk had an observed incidence of 53 CDIs per 1000 patients--more 
than 25 times higher than the lowest-risk decile. Pre-admission patient charac-
teristics that doubled the risk of CDI, were age 40 years or greater; use of high-risk 
antibiotics; chronic kidney disease requiring dialysis; liver disease; and more than 
7 days of hospitalization within 60 days. The score differentiated patients who 
develop CDI, an extended C-statistic of 0.75. Predicted risk for CDI agreed closely 
with observed risk. cOnclusiOns: Our risk score accurately predicted risk for CDI 
using pre-admission characteristics. Accurate predictions among the highest-risk 
subgroup of patients allow for the identification of patients who could be targeted 
for and who would likely benefit from pharmacist review of inpatient antibiotic 
use or educational efforts at the time of discharge planning, an improvement over 
simpler stratification strategies (e.g., class of antibiotic).
RI2
waRfaRIn dIsconTInUaTIon and sTRoke RIsk among paTIenTs wITH 
non-valvUlaR aTRIal fIBRIllaTIon
Wang J1, Qiao Y1, Spivey CA1, Liu X2, Phatak H3, Mardekian J4, Claflin AB4, Kachroo S3, 
Abdulsatter Y4, Parker RB1
1The University of Tennessee Health Science Center, Memphis, TN, USA, 2Pfizer, Inc. & University 
of Tennessee College of Pharmacy, New York, NY, USA, 3Bristol-Myers Squibb Company, Princeton, 
NJ, USA, 4Pfizer, Inc., New York, NY, USA
Objectives: To determine the association between warfarin discontinuation and 
stroke risk among patients with non-valvular atrial fibrillation (NVAF). MethOds: 
This is a historical cohort study of adult patients (≥ 18 years of age) with NVAF 
who were on warfarin in the MarketScan Commercial and Medicare Supplemental 
Claims and Encounters Database (01/2008-06/2012). Warfarin discontinuation was 
defined as a gap of ≥ 45 days in warfarin prescription within 1 year after initiation. 
Patients with and without warfarin discontinuation were matched at a 1:1 ratio 
using a propensity score method. Matched patients were followed for up to one year 
to determine risks of ischemic stroke, transient ischemic attack (TIA), and hemor-
rhagic stroke. Patient follow-up started from the discontinuation dates for discontin-
ued patients and after the same duration of warfarin therapy for matched persistent 
patients. A multivariate Cox proportional hazards model was used to determine the 
association between warfarin discontinuation and stroke risk after adjusting for 
patient baseline demographic/clinical characteristics. Results: A total of 27,000 
discontinued and persistent patients were included in the final analysis. According 
to the descriptive analysis, discontinued patients had higher rates of ischemic stroke 
than persistent patients (0.99 vs. 0.52 per 100 patient years, P< 0.001), while the rates 
of TIA (1.15 vs. 0.93 per 100 patient years, respectively; P= 0.13) and hemorrhagic 
stroke (0.25 vs. 0.19 per 100 patient years, P= 0.31) were similar between the two 
groups. After adjusting for patient characteristics, warfarin discontinuation was 
associated with significantly increased risk of ischemic stroke (hazard ratio [HR]: 
2.04; 95% confidence interval [CI]: 1.47-2.84) and TIA (HR: 1.36; 95% CI: 1.04-1.78) 
pared health outcomes (quality of life, productivity, resource use) across adherent 
vs. non-adherent respondents. Results: 369 respondents with valid adherence 
data were included in the analyses. Mean age was 62.5 years (SD= 10.5) and most 
respondents were insured (97.6%), nonsmokers (85.9%), and unemployed or disabled 
(65.0%). 23.3% were non-adherent at z-scores> 0 (corresponding to MMAS-4> 0 and 
MMAS-8> 1), and this did not differ significantly across the treatment groups. Across 
treatments, non-adherent vs. adherent behavior was associated with significantly 
poorer health utilities (0.684 vs. 0.734, respectively), worse mental health status 
(46.0 vs. 51.9), greater impairment while working (24.2% vs. 10.5%) and overall work 
impairment (24.9% vs. 13.7%), all p< .05. Non-adherence was associated with non-
significantly higher likelihood of hospitalization in the prior 6 months (24.4% vs. 
18.0%, p= .19). cOnclusiOns: Self-reported non-adherence to oral ET in women 
with BC was common and associated with statistically significant decrements in 
health-related quality of life, as well as work productivity impairments. Given the 
increasing use of oral ET in BC and detrimental effects of non-adherence, interven-
tions to improve adherence in those at highest risk should be developed and tested.
ma2
non-adHeRence To anTIplaTeleT THeRapy afTeR HospITalIzaTIon foR 
acUTe coRonaRy syndRome (acs) IncReases ReadmIssIons, moRTalITy, 
HealTH caRe Use and cosTs
Hill J1, Pokras SM1, Makin C1, Schabert VF1, Nelson M1, Foody J2
1IMS Health, Plymouth Meeting, PA, USA,, 2Brigham and Women’s Hospital, Boston, MA, USA
Objectives: Current practice guidelines recommend antiplatelet therapy (AT) for 
ACS patients during and after hospital discharge. Nonadherence has been associ-
ated with higher risks of thrombosis, MI and mortality. Real-world studies of AT 
adherence post-discharge have been limited by lack of access to inpatient prescrip-
tions. This study examines ACS mortality, hospital readmission, and health care 
costs by AT adherence post-discharge. MethOds: Patients hospitalized for ACS 
between 7/2009-7/2012 were identified from IMS Acute Coronary Syndrome Disease 
Records, which link patient-level information from IMS PharMetrics PlusTM health 
care claims data, IMS hospital charge data master, IMS ambulatory electronic medi-
cal record and mortality data derived from the Social Security Death Index. Patients 
with no diagnosis of ACS 180 days before hospital admission, and with confirmed 
inpatient AT therapy, were followed until the earlier of 360 days post-discharge or 
date of death. Adherence was measured by receipt of AT within 30 days post-dis-
charge and by proportion of days covered (PDC) for the 360 day period post-discharge 
or up to the dates of death and readmission. Adjusted estimates controlled for 
patient demographics and CV risk measured pre-index, using logistic regression, 
Cox regression, and GLM. Results: Of 2,994 patients selected for analysis, the 1,497 
(49%) filling a script for AT within 30 days post-discharge had lower mortality (1.6% 
vs. 6.4%, p< 0.0001), readmission rates at 30 days (7.8% vs. 14.6%, p< 0.0001), and costs 
($24,772 vs. $31,691, p= 0.001) compared to patients not filling. After adjusting for 
patient characteristics, higher compliance (PDC) post-discharge was associated with 
reduced risks of mortality (HR= 0.238, 95% CI: 0.158-0.359), readmission (HR= 0.423, 
95% CI: 0.364-0.512), and lower costs (p= 0.004). cOnclusiOns: Nonadherence with 
AT immediately after discharge and within 360 days was associated with higher 
mortality, readmissions, and costs. Study results show a significant opportunity to 
improve patient outcomes and reduce costs through higher AT adherence.
ma3
adHeRence and paTIenT RepoRTed oUTcomes In RHeUmaToId aRTHRITIs 
paTIenTs ReceIvIng BIologIc medIcaTIons: analysIs of specIalTy 
pHaRmacy pRogRam daTa
Olvey EL1, Crowe M2, Chandanais R2, Nolan R2, Rice G2
1NucleusX Market Access, Atlanta, GA, USA, 2Diplomat Pharmacy, Flint, MI, USA
Objectives: To describe the adherence and patient reported outcomes (PROs) of 
rheumatoid arthritis (RA) patients taking biologic drugs enrolled in a specialty phar-
macy (SP) program. MethOds: A retrospective analysis of pharmacy claims and 
PRO data for RA patients enrolled in a SP program and receiving biologic drugs from 
12/1/2011 through 10/31/2013 was conducted. Patients with a primary diagnosis of 
RA (ICD-9 CM: 714.xx) were included. Only those with at least two pharmacy claims 
and those with a baseline and at least one follow-up of PRO measures were analyzed. 
Patients who were < 18 or ≥ 90 years of age, who switched drugs or who declined 
involvement were excluded. Medication possession ratio (MPR) was used as a proxy 
for adherence and calculated based on pharmacy claims data. PROs were collected 
via telephone and included pain and fatigue measured on a numeric rating scale 
(NRS, scale: 0-10), and functional status measured using the Health Assessment 
Questionnaire-II (HAQ-II, scale: 0-3). Outcomes were collected at baseline and 
approximately every six months for the duration of the patients’ enrollment. 
Descriptive statistics, Wilcoxon signed-rank, and correlations were used to analyze 
the data. Results: A total of 2,385 patients were included. The mean age of patients 
was 54.80 years (±12.88) and 70.48% were female. The average MPR for all patients 
was 86.47% (±15.14%) over an average of 403.89 days (±167.20). Overall, 36.27% and 
38.87% of patients had at least 1-point decrease on the pain NRS and fatigue NRS, 
respectively. Any reduction in the HAQ-II score was observed in 46.79% of patients at 
follow-up, which was statistically significant (-0.065, p< 0.001). cOnclusiOns: RA 
patients receiving biologic medications enrolled in a SP program had high therapy 
adherence and realized decreases in pain, fatigue and improvement in functional 
status from baseline.
ma4
sysTemaTIc lITeRaTURe RevIew and meTa-analysIs of medIcaTIon 
adHeRence wITH once weekly veRsUs once daIly THeRapy In paTIenTs 
wITH osTeopoRosIs
Iglay K, Joshi K, Cao X, Mavros P, Tunceli K
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA
Objectives: To compare medication adherence rates for once weekly (QW) versus 
once daily (QD) dosing regimens in patients with osteoporosis. MethOds: A sys-
